Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer

The optimal sequence and combination of radium-223 therapy (Ra-223) for castration-resistant prostate cancer with bone metastasis (mCRPC) remain unclear. This study aimed to explore the prognostic factors after Ra-223 administration and to determine the optimal treatment strategy. We enrolled 64 pat...

Full description

Bibliographic Details
Main Authors: Yasuo Oguma, Makoto Hosono, Kaoru Okajima, Eri Inoue, Kiyoshi Nakamatsu, Hiroshi Doi, Tomohiro Matsuura, Masahiro Inada, Takuya Uehara, Yutaro Wada, Aritoshi Ri, Yutaka Yamamoto, Kazuhiro Yoshimura, Hirotsugu Uemura, Yasumasa Nishimura
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Radiation
Subjects:
castration resistant
prostate cancer
bone metastasis
radium-223
abiraterone
enzalutamide
Online Access:https://www.mdpi.com/2673-592X/2/3/21

Internet

https://www.mdpi.com/2673-592X/2/3/21

Similar Items